Generated August 29, 2026.
Overview
VHT and XLV are both healthcare equity ETFs tracking broad market indexes, but they differ meaningfully in scope and composition. VHT tracks the MSCI US Investable Market Health Care 25/50 Index, which includes small, mid, and large-cap healthcare stocks with diversification constraints. XLV tracks the Health Care Select Sector Index, which represents the healthcare holdings of the S&P 500 only—a large-cap-heavy universe. The result is that VHT casts a wider net across the healthcare landscape, while XLV focuses on the sector's mega-cap leaders.
How they differ
The core distinction is breadth: VHT includes small and mid-cap healthcare names alongside large-caps, whereas XLV's index includes only S&P 500 constituents, tilting the portfolio toward household names like UnitedHealth, Eli Lilly, and Johnson & Johnson. This makes XLV materially more concentrated in mega-cap exposure. XLV's yield of 1.53% exceeds VHT's 1.23%, though both distribute quarterly; XLV is also larger ($44.5B in AUM vs. VHT's $19.4B). VHT has a beta of 0.57 compared to XLV's 0.51, suggesting VHT carries modestly more systematic risk—consistent with its broader inclusion of smaller-cap healthcare equities, which tend to swing a bit more sharply in market moves.
Who each is best for
- VHT: Fits investors seeking healthcare sector exposure across the market-cap spectrum and preferring exposure to smaller healthcare companies alongside large-cap holdings.
- XLV: Designed for investors comfortable with concentration in large-cap healthcare leaders and attracted to a larger, more liquid fund with a modestly higher current yield and lower volatility profile.
Key risks to know
- Index concentration in large-cap names. XLV's S&P 500-only framework concentrates exposure in a smaller set of mega-cap healthcare firms; if large-cap healthcare valuations contract sharply, the impact on XLV may be steeper than on VHT's broader market-cap universe.
- Small and mid-cap liquidity for VHT. While VHT includes smaller healthcare stocks, those positions carry lower trading volume and wider bid-ask spreads than S&P 500 constituents, potentially increasing transaction costs during rebalances or large redemptions.
- Sector-level earnings and regulatory risk. Both ETFs are exposed to pharmaceutical pricing pressure, healthcare-policy uncertainty, and FDA approval risk; their beta values of 0.51–0.57 do not insulate them from sector-wide shocks (e.g., drug-pricing legislation or reimbursement cuts).
- Yield sustainability across market cycles. Healthcare dividend growth has historically lagged broad equity, and both distributions rely on earnings that can compress during economic slowdowns; current yields should not be assumed stable if sector earnings decline.
Bottom line
XLV offers larger AUM, higher yield, and slightly lower volatility through mega-cap healthcare leaders; VHT exposes investors to a broader cross-section of healthcare company sizes. If you value established large-cap healthcare exposure with strong liquidity, XLV's structure fits that profile; if you want exposure across market-cap tiers within healthcare, VHT's wider index membership stands out. Past performance doesn't predict future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.